Clinical signs—Schirmer test scores at 1 month (mm/5 min) · adult participants with chronic blepharitis
1 finding from 1 review
Clinical signs—TBUT at 1 month (seconds) · adult participants with chronic blepharitis
1 finding from 1 review
Adverse events at 1 month · adult participants with chronic blepharitis
It is very uncertain whether oral antibiotics changes adverse events at 1 month compared with placebo (very low certainty).
1 finding from 1 review
Quality of life measures · adult participants with chronic blepharitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Economic costs and benefits of different interventions · adult participants with chronic blepharitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Visual field sensitivity (visual field) · retinitis pigmentosa
1 finding from 1 review
Visual acuitychange in logMAR visual acuity, may be reported as ETDRS · retinitis pigmentosa
It is very uncertain whether vitamin A and fish oils (docosahexaenoic acid) changes visual acuitychange in logMAR visual acuity, may be reported as ETDRS compared with placebo, vitamins (including vitamin A), or no therapy (very low certainty).
1 finding from 1 review
Electroretinography (ERG) · retinitis pigmentosa
1 finding from 1 review
Optical coherence tomography (OCT) · retinitis pigmentosa
1 finding from 1 review
Adverse effects: as reported by studies · retinitis pigmentosa
1 finding from 1 review
Change in dry eye symptoms, measured using the OSDI score (ranging from 0 to 100 units, with a reduction in score indicating clinical improvement) at 1‐month (with actual · people with dry eyea
Oral long‐chain omega‐3 PUFAs (ie, EPA and DHA) showed no clear difference in change in dry eye symptoms, measured using the OSDI score (ranging… compared with placebo or no treatment (low certainty).
1 finding from 1 review
Tear film stability · people with dry eyea
Combined oral omega‐3 and omega‐6 PUFAs showed no clear difference in change in tear film stability, measured using tear break‐up time… compared with placebo (moderate certainty).
1 finding from 1 review
Change in tear osmolarity (measured in mOsmol/L, with reductions in osmolarity indicating clinical improvement) at 1‐month (with actual · people with dry eyea
1 finding from 1 review
Adverse event: gastrointestinal disorders at 1‐month (with actual · people with dry eyea
1 finding from 1 review
Change in ocular surface staining at 1‐month (with actual · people with dry eyea
Oral long‐chain omega‐3 PUFAs (ie, EPA and DHA) showed no clear difference in change in ocular surface staining at 1‐month (with actual compared with placebo or no treatment (low certainty).
1 finding from 1 review
Aqueous tear production · people with dry eyea
Oral long‐chain omega‐3 PUFAs (ie, EPA and DHA) showed no clear difference in change in Schirmer test (aqueous tear production, measured in mm/5… compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Tear film stability · people with dry eyea
1 finding from 1 review
Change in tear osmolarity (measured in mOsmol/L, with reductions in osmolarity indicating clinical improvement) at 1‐month (with actual · people with dry eyea
Oral long‐chain omega‐3 PUFAs (ie, EPA and DHA) showed no clear difference in change in tear osmolarity (measured in mOsmol/L, with reductions in… compared with placebo or no treatment (low certainty).
1 finding from 1 review
Adverse event: gastrointestinal disorders at 1‐month (with actual · people with dry eyea
1 finding from 1 review
Dry eye symptoms, measured using the OSDI score (ranging from 0 to 100 units, with a reduction in scores indicating clinical improvement) at 1‐month (with actual · people with dry eyea
1 finding from 1 review